The Discounted Cash Flow (DCF) valuation of Polydex Pharmaceuticals Ltd (POLXF) is 1.62 USD. With the latest stock price at 1.99 USD, the upside of Polydex Pharmaceuticals Ltd based on DCF is -18.3%.
Based on the latest price of 1.99 USD and our DCF valuation, Polydex Pharmaceuticals Ltd (POLXF) is a sell. Selling POLXF stocks now will result in a potential gain of 18.3%.
Range | Selected | |
WACC / Discount Rate | 5.3% - 6.6% | 5.9% |
Long-term Growth Rate | 0.0% - 1.0% | 0.5% |
Fair Price | 1.38 - 1.99 | 1.62 |
Upside | -30.4% - 0.1% | -18.3% |
(USD in millions) | Projections | |||||
01-2021 | 01-2022 | 01-2023 | 01-2024 | 01-2025 | 01-2026 | |
Revenue | 5 | 5 | 5 | 5 | 6 | 6 |
% Growth | 6% | -1% | 4% | 2% | 9% | 4% |
Cost of goods sold | (4) | (4) | (4) | (4) | (4) | (5) |
% of Revenue | 80% | 80% | 80% | 80% | 80% | 80% |
Selling, G&A expenses | (1) | (1) | (1) | (1) | (1) | (1) |
% of Revenue | 13% | 13% | 13% | 13% | 13% | 13% |
Research & Development | 0 | 0 | 0 | 0 | 0 | 0 |
% of Revenue | 0% | 0% | 0% | 0% | 0% | 0% |
Net interest & other expenses | (0) | (0) | (0) | (0) | (0) | (0) |
% of Revenue | 3% | 3% | 3% | 3% | 3% | 3% |
Tax expense | 0 | (0) | (0) | (0) | (0) | (0) |
Tax rate | 1% | 7% | 7% | 7% | 7% | 7% |
Net profit | 0 | 0 | 0 | 0 | 0 | 0 |
% Margin | 4% | 4% | 4% | 4% | 4% | 4% |